Literature DB >> 24686172

IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.

Yuzhe Yang1, Douglas Yee.   

Abstract

Insulin-like growth factors (IGF) stimulate cell growth in part by increasing amino acid uptake. xCT (SLC7A11) encodes the functional subunit of the cell surface transport system xC(-), which mediates cystine uptake, a pivotal step in glutathione synthesis and cellular redox control. In this study, we show that IGF-I regulates cystine uptake and cellular redox status by activating the expression and function of xCT in estrogen receptor-positive (ER(+)) breast cancer cells by a mechanism that relies on the IGF receptor substrate-1 (IRS-1). Breast cancer cell proliferation mediated by IGF-I was suppressed by attenuating xCT expression or blocking xCT activity with the pharmacologic inhibitor sulfasalazine (SASP). Notably, SASP sensitized breast cancer cells to inhibitors of the type I IGF receptor (IGF-IR) in a manner reversed by the reactive oxygen species (ROS) scavenger N-acetyl-L-cysteine. Thus, IGF-I promoted the proliferation of ER(+) breast cancer cells by regulating xC(-) transporter function to protect cancer cells from ROS in an IRS-1-dependent manner. Our findings suggest that inhibiting xC(-) transporter function may synergize with modalities that target the IGF-IR to heighten their therapeutic effects. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24686172      PMCID: PMC4006361          DOI: 10.1158/0008-5472.CAN-13-1803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Stressed tumor cell, chemosensitized cancer.

Authors:  Erik A C Wiemer
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  Therapeutic destruction of insulin receptor substrates for cancer treatment.

Authors:  Hadas Reuveni; Efrat Flashner-Abramson; Lilach Steiner; Kirill Makedonski; Renduo Song; Alexei Shir; Meenhard Herlyn; Menashe Bar-Eli; Alexander Levitzki
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

Review 3.  Targeting insulin and insulin-like growth factor signaling in breast cancer.

Authors:  Yuzhe Yang; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-10-10       Impact factor: 2.673

4.  Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer.

Authors:  Sora Baek; Chang-Min Choi; Sei Hyun Ahn; Jong Won Lee; Gyungyub Gong; Jin-Sook Ryu; Seung Jun Oh; Claudia Bacher-Stier; Lüder Fels; Norman Koglin; Christina Hultsch; Christoph A Schatz; Ludger M Dinkelborg; Erik S Mittra; Sanjiv S Gambhir; Dae Hyuk Moon
Journal:  Clin Cancer Res       Date:  2012-08-14       Impact factor: 12.531

Review 5.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

Review 6.  The insulin and insulin-like growth factor receptor family in neoplasia: an update.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

Review 7.  Insulin-like growth factor receptor inhibitors: baby or the bathwater?

Authors:  Douglas Yee
Journal:  J Natl Cancer Inst       Date:  2012-07-03       Impact factor: 13.506

8.  CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.

Authors:  Takatsugu Ishimoto; Osamu Nagano; Toshifumi Yae; Mayumi Tamada; Takeshi Motohara; Hiroko Oshima; Masanobu Oshima; Tatsuya Ikeda; Rika Asaba; Hideki Yagi; Takashi Masuko; Takatsune Shimizu; Tomoki Ishikawa; Kazuharu Kai; Eri Takahashi; Yu Imamura; Yoshifumi Baba; Mitsuyo Ohmura; Makoto Suematsu; Hideo Baba; Hideyuki Saya
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

9.  Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

Authors:  Dedra H Fagan; Ryan R Uselman; Deepali Sachdev; Douglas Yee
Journal:  Cancer Res       Date:  2012-05-09       Impact factor: 12.701

10.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Authors:  Luika A Timmerman; Thomas Holton; Mariia Yuneva; Raymond J Louie; Mercè Padró; Anneleen Daemen; Min Hu; Denise A Chan; Stephen P Ethier; Laura J van 't Veer; Kornelia Polyak; Frank McCormick; Joe W Gray
Journal:  Cancer Cell       Date:  2013-10-03       Impact factor: 31.743

View more
  22 in total

1.  Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.

Authors:  Katja Linher-Melville; Sina Haftchenary; Patrick Gunning; Gurmit Singh
Journal:  Mol Cell Biochem       Date:  2015-04-21       Impact factor: 3.396

2.  IGF-I stimulates ERβ and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.

Authors:  Yan Zhou; Cheng Zeng; Xin Li; Pei-Li Wu; Ling Yin; Xiao-Lan Yu; Ying-Fang Zhou; Qing Xue
Journal:  J Mol Med (Berl)       Date:  2016-02-22       Impact factor: 4.599

Review 3.  xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.

Authors:  Jinyun Liu; Xiaojun Xia; Peng Huang
Journal:  Mol Ther       Date:  2020-09-02       Impact factor: 11.454

Review 4.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

5.  Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.

Authors:  Yuzhe Yang; Jie Ying Chan; Nuri A Temiz; Douglas Yee
Journal:  Horm Cancer       Date:  2018-09-18       Impact factor: 3.869

6.  PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xc-) with [18F]FDOPA and [18F]FSPG in Breast Cancer Models.

Authors:  Daniel Krys; Stephanie Mattingly; Darryl Glubrecht; Melinda Wuest; Frank Wuest
Journal:  Mol Imaging Biol       Date:  2020-08-13       Impact factor: 3.488

7.  Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.

Authors:  Nian Liu; JiangLin Zhang; Mingzhu Yin; Hong Liu; Xu Zhang; Jiaoduan Li; Bei Yan; Yeye Guo; Jianda Zhou; Juan Tao; Shuo Hu; Xiang Chen; Cong Peng
Journal:  Mol Ther       Date:  2021-03-17       Impact factor: 12.910

8.  Regulation of System xc(-) by Pharmacological Manipulation of Cellular Thiols.

Authors:  Rebecca Albano; Nicholas J Raddatz; Julie Hjelmhaug; David A Baker; Doug Lobner
Journal:  Oxid Med Cell Longev       Date:  2015-04-09       Impact factor: 6.543

9.  Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.

Authors:  Eric Habib; Katja Linher-Melville; Han-Xin Lin; Gurmit Singh
Journal:  Redox Biol       Date:  2015-03-18       Impact factor: 11.799

10.  Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.

Authors:  Kimberly J Briggs; Peppi Koivunen; Shugeng Cao; Keriann M Backus; Benjamin A Olenchock; Hetalben Patel; Qing Zhang; Sabina Signoretti; Gary J Gerfen; Andrea L Richardson; Agnieszka K Witkiewicz; Benjamin F Cravatt; Jon Clardy; William G Kaelin
Journal:  Cell       Date:  2016-06-30       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.